Amgen Braces for Revenue Headwinds Amid Collaboration Termination
PILLAR DIAGNOSTIC // WEEK 05
“Biosimilar incursions into oncology and looming 340B litigation are capping Amgen’s revenue growth—a constraint the market’s bullish pipeline narrative has largely overlooked—setting the stage for a widening disconnect and eventual multiple repricing when these structural headwinds crystallize.”
Proposed action
Trim long exposure or hedge positions; avoid chasing further upside until map blockers clarify.
THE MECHANICS
Tape & flow
Shares have rallied 15.2% to $341.75 post-reporting, contributing to broad index upside as heavyweights drove 168.8 Dow points; options positioning shows a -0.40% Earnings ESP, pointing to downside skew into earnings, keeping the tape vulnerable to post-release volatility.
THE MACHINE
Operational momentum
Revenues grew to $9.56 billion, up 12.4% year-over-year, beating expectations and underpinning full-year guidance of ~$9.46 billion (+4.2% yoy). Pipeline expansion—including a shift toward dermatology and autoimmune assets and a promising once-monthly GLP-1 candidate—and the Horizon Therapeutics acquisition are driving product ramps, even as EPS are forecast to decline roughly 10.7%, reflecting margin pressure.
THE MAP
Structure & constraints
Strategic portfolio shifts have ended Amgen’s rocatinlimab collaboration and restored global control to Kyowa Kirin, while biosimilar competition depresses oncology revenue and high Teprotumumab pricing constrains thyroid eye disease access; 340B program litigation threatens repayment and punitive damages, even as TrumpRx participation and an $840 million acquisition advance pipeline development.
THE MOOD
Consensus & positioning
Valuation discounts and potential late-stage pipeline catalysts, including an obesity drug and Phase 3 trial readouts, have fueled cautious optimism among investors, though looming earnings declines, mixed analyst downgrades and uncertain guidance revisions temper enthusiasm.
